Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study.
Von Hoff
D D
DD
University of Texas Health Science Center, San Antonio.
Green
S J
SJ
Neidhart
J A
JA
Fabian
C
C
Budd
T
T
Boyd
J F
JF
Osborne
C K
CK
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000409:Alanine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged
D000903:Antibiotics, Antineoplastic; C000082:alanosine; D000409:Alanine